Physician profile
Temitope Foster
NPI 1356538615
$10,297.82
in general payments reported to CMS, 2019-2025
37 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $1,088 · 2021: $1,304 · 2022: $1,057 · 2023: $1,265 · 2024: $1,699 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596 · Education: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,595.69 |
| Education | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,585.64 | 2019-2025 | |
| Apollo Endosurgery US INC | $874.03 | 2019 | |
| Novo Nordisk INC | $858.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Biotech, INC. | $791.66 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Ardelyx, INC. | $774.25 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $556.53 | 2019-2025 | Tremfya |
| Romark Laboratories, Lc | $530.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $525.67 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $301.95 | 2019-2024 | Entyvio, Gattex |
| Braintree Laboratories, INC. | $279.00 | 2019-2023 | Sutab |
| Gilead Sciences, INC. | $273.34 | 2019-2024 | Epclusa |
| Lilly USA, LLC | $249.58 | 2023-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $213.78 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $201.19 | 2020-2022 | |
| Pfizer INC. | $191.95 | 2023-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $143.81 | 2022-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $100.12 | 2020-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $98.32 | 2019-2024 | |
| Genzyme Corporation | $82.47 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $81.42 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $80.13 | 2024-2025 | Resmetirom, Rezdiffra |
| Daiichi Sankyo INC. | $72.52 | 2020-2023 | Injectafer |
| Allergan, INC. | $65.67 | 2019 | |
| Organon LLC | $56.08 | 2023-2025 | Renflexis, Hadlima |
| Celltrion USA INC. | $44.09 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $41.47 | 2024 | Iqirvo |
| Ucb, INC. | $32.26 | 2019 | |
| Csl Behring | $27.72 | 2021 | |
| Ferring Pharmaceuticals INC. | $23.38 | 2019 | |
| Vivus LLC | $21.46 | 2024 | Qsymia |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Celgene Corporation | $18.62 | 2024 | Zeposia |
| Endo Pharmaceuticals INC. | $17.54 | 2019 | |
| Capsovision, INC. | $16.94 | 2023 | Capsocam Plus |
| Fresenius Kabi USA, LLC | $16.05 | 2023 | Idacio |
| Alfasigma USA, INC. | $15.97 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temitope Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.